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Abstract
Background: Due to the efforts in malaria control promoted by the World Health Organization (WHO), the
reported malaria burden is being reduced throughout the world. Nevertheless, malaria remains a leading cause of
child death worldwide.
Aims: purpose of the paper is to summarize the main historical steps in fighting malaria, from the first descriptions
to the last ones.
Results: a case of probable autochthonous malaria has been recently described in Italy, raising concern over the
possibility of resurgence of malaria in countries previously interested by this disease. Moreover, both the constant
threat of the parasite and vector mosquito developing resistance to medicines and insecticides, and the on-going
climate change make the challenge of eradicating malaria really difficult. Therefore, malaria is still an actual disease,
requiring adequate programs of surveillance, stronger health systems in poor countries, and efforts in order to
develop new and effective tools in malaria control. WHO has definitely demonstrated the effects of “social
determinants” on health. So, eradication strategies cannot be based only on a scientific background, because
culture, politics, power, resources and wars have a profound impact on health and disease. These elements should
be introduced in all the programs of malaria control.
Conclusions: malaria is still an actual disease with great public health implications, and the approaches for control
and prevention should have the appropriate social and political context in addition to the science involved in
order to save lives of children at risk.
Background
Malaria is a protozoal disease, transmitted by the Ano-
pheles species mosquito carrying the Plasmodium para-
site. It is the most important protozoal disease to affect
man, with transmission, until today, documented in 103
countries, affecting more than 500 million people per
year, causing between 1 and 3 million deaths, especially
children under 5 years, pregnant women and not
immune people. Today, malaria is common, above all,
in the tropical and sub tropical areas of the world. In
some areas of Italy, as in the majority of Mediterranean
countries, malaria has beenknown for centuries and the
prevalence was reduced only since 1947 [1].
At the beginning of the 20
th century, malaria was the
biggest problem facing Italian public health. It caused low
productivity, poverty and economy underdevelopment.
However, Italy became one of the most important world
centre for the development of the study of malaria and it
was the first country to launch a national campaign to
combat the disease. The defeat of malaria was linked with
the extension of civil liberties, the spread of education and
improvements in the general health of population [2].
S i n c et h ee n do f1 8 0 0 ,i nI t a l ye v e r yy e a rt h e r eh a d
been 15,000 deaths from malaria, above all in the South.
Nevertheless, in Italy has been recently reported a case
of malaria, interesting a 44 year old man who had not
travelled out of Italy and probably contracted malaria in
the Agro Pontino, a former malaria endemic area in
Italy [3].
Methods
Bibliografic research on both Italian and not-Italian
books of history of medicine and on MEDLINE/
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torical and upcoming steps that shaped the complex
relationship between man and the malaria parasite.
Table 1 summarizes the main steps about the history
of malaria.
Results
Main historical steps
It is likely that the history of malaria closely follows the
history of man. It is widely held that the parasite was pre-
sent in the ancestors of the Homo Sapiens. Seasonal or
intermittent fevers are well documented in ancient civili-
z a t i o n ss u c ha st h eS u m e r i a n ,t h eA s s y r i a n - B a b y l o n i a n ,
the Egyptian, the Indian and the Chinese. From these
civilizations different written testimonies have survived.
The Ebers Papyrus (about 1570 BC) describes the symp-
toms of the disease, making reference to the enlargement
of the spleen accompanied by fever. The Atharvaveda (an
ancient Indian text dated about 1000 BC) describes the
symptoms and recurrence of the malaria fever. The first
detailed clinical description of malaria, however, fell to
Hyppokrates of Kos, who in the aphorisms of his work
Epidemie described the typical intermittent fever.
The origins of malaria remained unknown for centu-
r i e s .I tw a st h o u g h tt h a tm i a s m a so r“bad air” above
stagnant water caused the disease. Indeed, the etymol-
ogy of the word “malaria” (bad-air) stems from the con-
viction that the disease was caused by miasmas from
marshy areas.
In the sixteenth century a different theory regarding
the cause of the disease emerged. In 1546, Girolamo
Fracastoro (about 1483-1553) from Verona, who studied
and was a lector in Padova, as well as being a doctor on
the Council of Trent, published De Contagiose et Conta-
giosis Morbis.
In this work he argued that the “contagion” was the
mechanism for the transmission of the disease. The
rules for human quarantine were subsequently based on
this theory [4].
In 1880 in Constantine, Algeria, Alphonse Laveran
identified the protozoan for the first time in peripheral
human blood. In Rome Ettore Marchiafava and Angelo
Celli studied it and named it Plasmodium.I nP a v i a ,i n
1885, Camillo Golgi (Nobel Prize winner, 1906), demon-
strated the association between the recurrence of the
malaria fever and the life cycle of the plasmodium.H e
also demonstrated that the two types of malaria fever,
the tertiary and the quaternary, were caused by two
different species of plasmodium:t h eP. vivax was
r e s p o n s i b l ef o rt h et e r t i a r yb e n i g nt y p ea n dt h e
P. malariae for the quaternary. In 1889 he demonstrated
that the fever attacks begin after the first round of blood
schizogony. In Rome, Ettore Marchiafava, Angelo Celli,
Amico Bignami and Giuseppe Bastianelli demonstrated
the existence of the P. falciparum, responsible for the
tertiary malignant type of malaria.
In China in 1894, Patrick Manson hypothesized that
which in India in 1897 Ronald Ross (Nobel prize
Table 1 Main steps about the history of malaria
Historical period Events
Ancient history
- ≈ 1570 BC Ebers Papyrus: description of symptoms (fever and spleen enlargement);
- ≈ 1000 BC Atharvaveda: description of symptoms and recurrence of the fever;
- ≈ 460 - 370 BC Hyppokrates of Kos in his work Epidemie describes the intermittent fever;
- 340 AD Ge Hong, China, describes the anti-fever properties of qing hao.
17
th century First description of Peruvian bark (Cinchona), from which quinine is extracted.
1880 Alphonse Laveran: the discovery of the Malaria parasite.
1885 - 1889 Camillo Golgi: the differentiation of different form of Malaria.
1897 - 1898 Ronald Ross: the Plasmodium is transmitted by “a mosquito”.
1898 - 1899 Giovan Battista Grassi: the Plasmodium life cycle.
1905 - 1910 The control of malaria and yellow fever make possible the construction of the Panama Canal.
1914 - 1942 The U.S. Public Health Services and the U.S. Tennessee Valley Authority: the integration of Malaria control with the U.S. economic
development
1934 - 1946 A new antimalarial drug: chloroquine.
19
th -2 0
th
century
- 1874 Othmar Zeidler describes the synthesis of DDT;
- 1939 Muller demonstrates the insecticidal property of DDT
1955 - 1978 WHO Malaria Eradication Efforts: an unsuccessful “global” campaign with the exclusion of sub-Saharan Africa.
21
st century The knowledge of genetic map and the research for an effective vaccine.
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mitted to man by “a mosquito”.
In Rome in 1898, Giovanni Battista Grassi identified
the Anopheles species as the mosquito carrier of malaria
and managed to carry out the first ever experimental
transmission. In 1899 he described the complete life
cycle of the various species of the Plasmodium.G r a s s i
had observed that in places where malaria was rife,
there were always mosquitoes. However, not always
where there were mosquitoes there was malaria. As a
result he hypothesized that only a few species of mos-
quito could transmit the disease. He spent his summer
holidays searching for the suspect “monster mosquito”
that appeared only at dusk and had four small light
brown narks on its wings, and a raised abdomen: the
Anopheles Claviger. Grassi entered the homes of those
sicks with malaria and asked them about the bites they
had received and their habits. He catalogued around 40
species present in Italy. On the 28
th of September 1898,
at the Lincei Academy, Grassi read a communication in
which he assured his audience that only the Anopheles
mosquito and two other species were suspected of
transmitting the disease. That autumn Grassi allowed a
friend, Mr Sola, to be bitten numerous times by the
Anopheles mosquito. Mr Sola was infected and his blood
resulted positive for the presence of malarial parasites.
After Mr Sola, the patients of an entire ward of the
Santo Spirito Hospital (Rome) were bitten by mosqui-
toes deliberately freed; they were all infected and all
came down with malaria. Grassi demonstrated that only
the Anopheles mosquito was responsible for the trans-
mission of malaria from man to man and that bird
malaria could not be transmitted by the same mosquito
responsible for human malaria. He taught people in
infected areas not to go out at dusk but to stay in their
homes and prevent mosquitoes from entering.
In this same period, new research brought along the
discovery of a product which would come to represent a
cornerstone in the fight against malaria. In 1874, an
Austrian student, Othmar Zeidler, while defending his
doctoral thesis at the University of Strasbourg, described
the synthesis of DDT created by allowing chlorobenzene
and chloral to react together. The results of his research
were published in 1874. In 1939, Muller demonstrated
the insecticidal activity of DDT. In 1940, the compound
was patented and in Switzerland in 1941 the first pro-
ducts containing DDT were sold.
The first campaign using DDT began in Naples in
1944, in order to tackle a typhus epidemic. Over 3 mil-
lion individuals, both civilian and military were “dusted”
with the mixture of insecticide. DDT began to develop
its reputation as the “miracle insecticide”.I tt h e n
showed its effectiveness against mosquitoes carrying
malaria in the Pacific. From 1947 to 1952, areas with
malaria in Italy were subjected to treatment with DDT,
which helped to weaken the disease. In the world, the
World Health Organization (WHO) estimated that in
the first 8 years of use, DDT prevented at least 100 mil-
lion cases of malaria and 5 million deaths. In 1948, Mul-
ler was awarded the Nobel Prize for Medicine for the
discovery of the strong insecticidal action of DDT. In
1955, the WHO launched a “global” campaign to eradi-
cate malaria in the world, based on the use of DDT,
even though most countries in the sub-Saharan Africa
(the area most afflicted by the disease) were completely
excluded from the campaign efforts. This brought about
a weakening of the disease in developed countries and
in many areas of Asia and Latin America. In 1969, the
global campaign was interrupted by difficulties, above
all, in areas with a high incident rate of the disease
(Sub-Saharan Africa). During the campaign to control
malaria, DDT showed a lot of side effects, both on man-
kind and environment. Indeed, in 2001 the Stockholm
Convention gave permission for the production and use
of DDT for the control of vectors of diseases, in particu-
lar malaria. However, conditions set out in the treaty
would have to be followed and its use could only occur
after specific recommendation from the WHO [5].
At the beginning of 2000, the knowledge of the
genetic map of the malaria parasite gave hope that new
action plans could be developed as well as new thera-
peutic targets and plans for the development of a
vaccine [6][7].
Treatment
Today therapeutic strategies are based on an “intercul-
tural collaboration”, which relies on the use of mosquito
nets, DDT and multi-drug cocktails. Different schools of
thought are united by the common and ambitious objec-
tive: to weaken one of the most insidious and long-lived
diseases in the history of mankind.
Medical treatment dates back to antiquity when each
attempt was based on relative theories of how and
where the disease originally developed. Such theories
relied on people’s observations of the disease and on
what they believed were the truths about the universe,
life, illness and god.
Ronald Ross, the first to find the malaria parasite and
later awarded the Nobel Prize, believed in attacking the
carrier, by blocking mosquitoes and protecting oneself
w i t han e ta n dn o tl i v i n gn e a rt h em i a s m a s .H ew a sa
firm believer in the theory of miasmas and used it as a
base for his fight to control malaria. He was convinced
that creatures living in the “miasmatic” environment
were responsible for the transmission of malaria.
Robert Koch believed in the necessity of preventative
treatment with quinine for anyone in an area hit by
malaria. His approach was to “treat the patient not the
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for a healthy patient, based on the belief that malaria
was a “germ” passed from person to person.
The control of malaria has drawn from both para-
digms. Naturally miasmas are part of and have effects
for the entire community. Ross wanted to eliminate
them. The Italians did it in the Agro Pontino with Mus-
solini (a particularly shocking aspect to the history of
this area is mentioned in Snowden’s book [2] and
describes how the retreating Nazi armies in Italy in
1943-44 deliberately caused a massive malaria epidemic
in Lazio. It was “t h eo n l yk n o w ne x a m p l eo fb i o l o g i c a l
warfare in 20
th-century Europe”). They drained the
marshland between Rome and the sea, which drastically
reduced the spread of malaria in that area. Koch recom-
mended the widespread use of quinine to colonial gov-
ernments. The program for the eradication of malaria of
the WHO also focused on the use of DDT, even though
only after specific recommendation and in selected cases
[8][9].
Artemisinine is the endoperoxide of a sesquiterpene
lactone derived from the infesting plant qing hao,a l s o
known as sweet or annual wormwood. The Chinese
attributed medical properties to this plant more than
2000 years ago. In 340 AD, Ge Hong prescribed tea of
qing hao as a remedy for feverish attacks and in 1596,
Li Shizhen recommended it for the relief of the symp-
toms of malaria.
In 1972, Chinese researchers extracted and crystallized
the principle anti-malarial component, qinghaosu,n o w
known as artemisinin. Artemisinin has now been
replaced by three more powerful semi synthetic deriva-
tives, which are more widely available: dihydroartemisi-
nin, artemether and artesunate.
Quinine is the main alkaloid extracted from the pow-
dered bark from the quina plant (Cinchona) from South
America, also known as Peruvian, Jesuit or cardinal
bark. The name of Cinchona for the “fever tree” came
into existence as a result of the successful treatment of
the countess of Quinhon, wife of the Spanish Vice-king
of Peru. She was suffering from malaria and was given
the indigenous medicine, bark of the “fever tree”.I tw a s
used by the indigenous Peruvians as a cure for the shi-
vers. In 1633 an Augustinian monk called Calancha
from Lima, Peru, was the first to report that the powder
of the cinchona plant “given as a drink cures fever and
tertian”. In 1640, cinchona was used to cure fever in
Europe. The Jesuit Fathers were the main importers of
cinchona in Europe. For almost two centuries the bark
of the cinchona tree was used in medicine as a powder.
In 1820 Pelletier and Caventou isolated quinine from
cinchona bark. Quinine is still today fundamental to the
cure of attacks of malaria from P. falciparum resistant
or multi-resistant to chloroquine.
Chloroquine has been valued during a collaborative
program of research into anti-malarial drugs during the
Second World War. Starting in 1943, thousands of these
compounds were synthesized and tested for their anti-
malarial activity. Chloroquine showed itself to be the
most promising. At the end of the war it was discovered
that the same compound had been synthesized and stu-
died under the name of Resochin by the Germans since
1934, but it had been rejected because of the toxicity
demonstrated after testing on birds [10].
However, one of the largest present medical emergen-
cies is the ever increasing resistance to drugs used to
treat the most important micro-organisms that attack
mankind. This has been caused by the large scale and
often incongruous use of various anti-microbial drugs.
This problem can naturally concern the fight against
malaria. Preliminary studies have highlighted this pro-
blem. In a randomized study published in the New Eng-
land Journal of Medicine (NEJM), 94 adults from the
Battambang province, in West Cambodia, with non
complicated malarial infection from P. falciparum were
treated with artesunate (4 mg per kg of body weight per
day, for 7 days), or quinine (30 mg per kg per day) in
addition to tetracicline (25 mg per kg per day) in sepa-
rate doses every 8 hours for 7 days. Patients were
observed for 28 days after the first day of treatment.
Four patients had an increase in parasitemia between
the 21
st and the 28
th day, of these, two were classified as
resistant to artesiminin, in adherence with the para-
meters set by the authors of the study. This study
showed that artesiminine is still a powerful drug, which
reacts very quickly, allowing little time for the parasites
to modulate their genes in order alter the targets of the
drug. Nevertheless, the widespread use of this drug, with
the demonstration in this work of the theoretical possi-
bility of resistance to artesiminine resulting from the
long time period required for the clearance of the para-
site, makes the discussion over resistance more proble-
matic. It also underlines the importance of the
production of a vaccine, not only for these areas but for
all of humanity [11].
A recent discovery (2010) has opened new futuristic
scenarios about the identification and development of
new strategies on how to control the spread of malaria.
A study published on Nature by Modiano et al (“La
Sapienza” University, Rome) demonstrated that variants
in genes that have been shown to be protective against
malaria (hemoglobins C (HbC, beta6Glu–>Lys) and S
(beta6Glu–>Val)) were associated with an increase of
parasite transmission from the human host to the ano-
pheles vector. This is an example of how genetic varia-
tion may influence the transmission dynamics of an
infectious disease. The host-vector transmission can be
affected also by genetics factors [12].
Buonsenso and Cataldi Italian Journal of Pediatrics 2010, 36:58
http://www.ijponline.net/content/36/1/58
Page 4 of 7Vaccine
An effective vaccine for malaria has been the subject of
research for over 70 years. Various antigens have been
identified as potential targets for the development of an
anti-malaria vaccine.
One of these, the repetitive sequence of 4 amino acids
of the antigen of the circumsporozoite on the surface of
the Plasmodium falciparum, forms the basis of the RTS,
S vaccine. Initial results on human volunteers indicate
an effective protection of 40% when the vaccine is used
in combination with an effective adjuvant therapy. This
vaccine would have an estimated effectiveness of about
30% in its capacity to reduce episodes of clinically mani-
fested illness, and about 40% in cases of new infection.
In the NEJM, Abdulla et al [13] described the trial in
which the RTS,S vaccine was used in combination with
the adjuvant AS02 D. The result was a reasonable effec-
tiveness when compared to the Hepatitis B vaccine and
the strength of anti-circumsporozoite anti-bodies was
recoverable in 98% of infants who received the vaccine.
In this trial, the vaccine was given together with other
vaccines (diphtheria vaccine, tetanus toxoid, whooping
cough, Haemophilus influenzae type b) as foreseen by
the schedule of the Expanded Program on Immuniza-
tion (EPI). There was no interference with the other
vaccines. This led scientists to believe that it could be
administered together with other vaccines in areas
where malaria is endemic. During the six months of
observation following immunization, the incidence of
malaria infection and clinical illness of the group RTS,S
was reduced by 65% and 59% respectively. There was a
correlation between the reduction of the risk of infec-
tion and the increase in the strength of circumsporo-
zoite anti-bodies but there was no association between
the reduction of the incidence of clinically manifested
m a l a r i aa n dt h es t r e n g t ho fa n t i g e n s .B e j o ne ta l[ 1 4 ]
published on the NEJM the results of a trial of phase 2b
regarding the effectiveness and safety of the RTS,S vac-
cine when combined with the ASOIE adjuvant for chil-
dren aged between 5 and 17 months. The vaccine was
associated with less collateral effects when compared to
the anti-rabies vaccine. It had a 60% effectiveness
against episodes of malaria clinically manifested from
the P. falciparum, with anticircumsporozoite antibodies
present in 99% of those vaccinated. Even in this case
there was no correlation between the protection against
clinically active malaria and antibody strength. In this
vaccine the antibody strength was about 10 times super-
ior to Abdulla’s vaccine, but the effectiveness is analo-
gous. It is not demonstrated whether the higher
antibody strength is associated with a longer duration of
effective protection. Acquired immunity against one
form of malaria parasite, does not mean protection
against the other forms. The target of the RTS,S vaccine
is the sporozoite. Therefore, if the immunity acquired
by the vaccine fails to block even one sporozoite, this
can lead to the hepatotropic stage and from there to the
erythrocyte phase and then to illness. Even though the
first results are promising, the incidence rate of malaria
in the studied areas was low. In addition, the evaluation
of the vaccine has been complicated by the widespread
use of insecticides and treatment programs based on the
use of artemisinine. For example, in areas where malaria
is endemic, such as Gambia in western Africa, and in
Kenya and Tanzania in the east, there has already been
an important reduction in the force of malaria. These
data make statistical interpretation of the obtained
results more difficult. In 2009, the RTS,S vaccine will
begin phase 3 of the trial, even in areas where transmis-
sion of malaria is moderately high. This is the first anti-
malaria vaccine to reach phase 3 and the forthcoming
studies in areas with high transmission levels will allow
scientists to understand the true value of this vaccine.
Even though the vaccine against malaria is still at a very
early stage of development and nobody knows at this
time whether a sufficiently effective and affordable vac-
cine against malaria will ever see the light, it is a pro-
mising start [15].
Malaria and cancer
Malaria is not only an infectious disease: the relationship
between endemic Plasmodium falciparum malaria and
Epstein-Barr virus (EBV) infection in the genesis of
endemic Burkitt’s lymphoma (eBL) is well established.
eBL, the most prevalent childhood cancer in equatorial
Africa, is a high-grade B cell lymphoma characterized by
a c-myc translocation and the consistent presence of
EBV. After primary infection, EBV establishes a lifelong
persistent infection. Afric a nc h i l d r e na r ei n f e c t e db y
EBV early in life while seroconversion tends to occur
later in developed countries.
Acute and chronic malaria infections profoundly affect
the B cell compartment, inducing polyclonal activation,
hyper-gammaglobulinemia and a dramatic increase in
the levels of circulating EBV. A recent study showed
data suggesting a molecular link between the parasite,
the B cell and EBV: the cystein-rich inter-domain region
1( C I D R 1 )o ft h ePlasmodium falciparum erythrocyte
membrane protein 1 (PfEMP1) seems to function as a
polyclonal B cell activator. CIDR1 increases B cell survi-
val and activates the memory compartment where EBV
is known to persist. Moreover, P. falciparum antigens
such as PfEMP1 can directly induce EBV reactivation
during malaria infections. In conclusion, the increased
viral load and the concomitant polyclonal B cell activa-
tion with enhanced B cell survival may augment the
risk of eBL development in children living in malaria-
endemic areas [16][17].
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Malaria infection during pregnancy is one of the contri-
butors to neonatal mortality, mostly through low birth
weight (LBW) and by causing maternal anemia [18].
In malaria stable transmission areas in Africa, approxi-
mately 25 million pregnancies are exposed every year to
the infection. In these areas, WHO recommends preven-
tive strategies during pregnancy [19][20].
These measures are based on the administration of
intermittent preventive treatment (IPTp) and the use of
insecticide treated nets (ITNs).
IPTp is the administration of two or more treatment
doses of an effective antimalarial drug given at defined
intervals during pregnancy. The currently recommended
regimen for IPTp is at least 2 treatment courses of sul-
phadoxine-pyrimethamine (SP) given from the 2
nd tri-
mester onwards at least one month apart. It acts as
treatment of existing infections (symptomatic or not)
and as prophylaxis by limiting the development of infec-
tion for an interval of time in pregnancy [21].
In a recently published trial, it was found that IPTp
with SP was associated with a moderate but significant
reduction in the incidence of clinical malaria during
pregnancy, and with a statistically significant reduction
in the prevalence of parasitaemia at delivery and at
8 weeks postpartum, as well as in fetal anemia in cord
blood [22].
However, the uptake of these tools varies between
countries but it is still far from covering the majority of
the pregnant women at risk of malaria in Africa [23].
Nevertheless, it is not yet well established if these stra-
tegies are associated with a minor prevalence of low
birth weight (LBW), prematurity or maternal anemia at
delivery [21][24].
On the other hand, a recent work shows that IPTp in
pregnancy in regions with high malaria transmission
and high drug resistance may increase the overgrowth
of resistant parasites and worsen malaria infections [25].
In malaria-endemic areas, pregnancy increases sus-
ceptibility to infections by the malaria parasite Plasmo-
dium falciparum. Pregnant women with P. falciparum
malaria are more likely to have LBW babies and to suf-
fer from anaemia, especially during their first pregnancy.
Identifying the determinants of immunity to malaria in
pregnancy is critical to understanding the pathogenesis
of the disease, and having a reliable and convenient mea-
sure of protection from infection in pregnant women
who live in endemic regions is an important goal for
local and international public health authorities [26].
Discussion
More than one hundred years have passed since
Laveran, Ross and Grassi discovered the details of
malaria transmission. Nevertheless, malaria is still an
actual disease with great public health implications: still
today more than 500 million people in the world con-
tract malaria every year and 1 million people die, overall
children.
Malaria is an actual but above all potential concern,
b e c a u s eo fs o m ee l e m e n t st h a t could further affect its
epidemiology and treatment:
1. Climate changes could recreate favorable environ-
mental conditions may increase the spread of the
disease in areas that already experience serious pro-
blems. Scientists have developed models to predict
the effects of climate change on malaria spread in
the next decades. Many of these models predict an
expansion in the transmission of the disease in the
next thirty years. The data provided by the MARA
project (Mapping Malaria Risk in Africa) predict
that, if the population does not increase, in 2100 in
Africa the percentage of people exposed to malaria
will be 16-28% more than today [27].
2. Treatments nowadays available may no longer be
as effective as they presently are because of increas-
ing threat of drug resistance.
3. The administration of anti-malarial drugs is no
doubt more difficult in countries where the socio-
cultural context is different from developed coun-
tries one. The introduction of an effective vaccine
could certainly be a solution to this problem because
of its easier way of administration. Moreover, it
could represent a “problem” for its wide distribution
in poor countries the fact that western market will
regulate the access to an eventual vaccine.
4. The approaches to prevent and control diseases
have their roots in science, but not only; the control
programs for the disease have a social and political
context that is not merely scientific. Our science is
based on a historic-political-cultural-social context
different from that of countries where malaria bur-
den is higher. Our context is a “Northern one”,w i t h
its roots in Western civilization. But nowadays
malaria is in the “South”, in tropical countries of the
Third World, in Latin America, in Africa, in South-
East Asia, places not rooted in the Western context.
Actual programs for the control of malaria could
therefore contrast with the indigenous contexts [8].
An important step forward would therefore be to
think of a way of controlling malaria in agreement with
all these elements. Motivation of populations and gov-
ernments and the firm will and ability to establish effec-
tive health care systems are a prerequisite for
undertaking malaria control.
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